You are here

  • Home
  • Archive
  • Volume 17, Issue 4
  • Some oral antidiabetic medications may prevent Type 2 diabetes in people at high risk for it, but the evidence is insufficient to determine whether the potential benefits outweigh the possible risks

Article Text

Article menu
Download PDFPDF
Therapeutics
Systematic review and meta-analysis
Some oral antidiabetic medications may prevent Type 2 diabetes in people at high risk for it, but the evidence is insufficient to determine whether the potential benefits outweigh the possible risks
  1. Andrew J Krentz
  1. Bedfordshire & Hertfordshire Postgraduate Medical School, University of Bedfordshire, Luton, UK
  1. Correspondence to Andrew J Krentz
    Bedfordshire & Hertfordshire Postgraduate Medical School, University of Bedfordshire, Putteridge Bury Campus, Hitchin Road, Luton, LU2 8LE, UK; andrew.krentz{at}beds.ac.uk

https://doi.org/10.1136/ebmed-2011-100332

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Phung OJ, Sood NA, Sill BE, et al. Oral anti-diabetic drugs for the prevention of Type 2 diabetes. Diabet Med 2011;28:948–64.OpenUrlCrossRefPubMed

    Context

    Type 2 diabetes has its origins in obesity-associated insulin resistance compounded by a progressive inability to secrete adequate amounts of insulin in compensation. Clinical trials have shown that non-pharmacological strategies can reduce the risk of progression of glucose intolerance to diabetes in obese glucose-intolerant individuals. All too often however, clinical practice exposes the difficulties that many people have in achieving and sustaining lifestyle changes. Alternative strategies for diabetes prevention have therefore been sought.

    Methods

    In this meta-analysis, Phung et al identified randomised controlled studies (placebo or active comparator) of at least 3 months duration that each enrolled at least 20 participants. In addition to a conventional meta-analysis, the authors performed a mixed-treatment comparison. The aim of the latter analysis was …

    View Full Text

    Footnotes

    • Competing interests AJK has received professional consultancy fees, grant funding and/or fees for consultancies and lectures from Astra Zeneca, Bayer, Bristol-Myers Squibb, Eli Lilly, NovoNordisk, Pfizer, Servier and Takeda.